BioCentury | Oct 15, 2012
Strategy

At home with Servier

...these indications. Servier includes osteoporosis in rheumatology. Its sole program in this therapeutic area is NB S101...
BioCentury | Aug 15, 2011
Company News

Osteologix musculoskeletal news

...ceased. The company said it is seeking to minimize overhead expenses, while focusing on its NB S101...
...for the compound. Last year, Osteologix granted Servier exclusive, ex-U.S. rights to develop and commercialize NB S101...
BioCentury | Dec 20, 2010
Company News

Osteologix musculoskeletal news

...Osteologix had $4.1 million in cash and nine-month operating gain of $836,000. Osteologix's lead candidate, NB S101...
BioCentury | Aug 9, 2010
Company News

Osteologix, Servier deal

...and commercialize NB S101 to treat postmenopausal osteoporosis, other bone and joint disorders, and dental indications. NB S101...
BioCentury | May 19, 2008
Clinical News

NB S101: Phase III start

...of oral NB S101 given once daily. Osteologix Inc. (OTCBB:OLGX), San Francisco, Calif. Product: NB S101 (formerly NBS-101...
BioCentury | Nov 12, 2007
Finance

Ebb & Flow

...see B15). Osteologix (OLGX) gained $0.63 (54%) to $1.80 on the week after reporting that NB S101...
BioCentury | Nov 12, 2007
Clinical News

NB S101: Phase II data

...In the double-blind, U.K. and Danish Phase II STRONG trial in 289 postmenopausal women, NB S101 met...
...by 13.5%, 15.5% and 22.2% in patients receiving 750, 1,000 and 2,000 mg of once-daily NB S101...
...treat and prevent osteoporosis in Europe. Osteologix Inc. (OLGX), San Francisco, Calif. Product: NB S101 (formerly NBS-101...
BioCentury | Nov 6, 2007
Clinical News

Osteologix's NB S101 meets osteoporosis endpoint

...OLGX said NB S101 (formerly NBS-101 ) met the primary endpoint of a significant reduction in serum...
...by 13.5%, 15.5% and 22.2% in patients receiving 750, 1,000 and 2,000 mg of once-daily NB S101...
...ranelate, which reduced CTX-1 levels by 8.5% vs. placebo (p=0.03). The 2,000 mg dose of NB S101...
BioCentury | Apr 23, 2007
Clinical News

NB S101: Completed Phase II enrollment

...U.K. and Danish Phase II STRONG trial comparing 750, 1,000 and 2,000 mg of once-daily NB S101...
...stronium ranelate from Servier (Neuilly-sur-Seine, France). Osteologix Inc. , San Francisco, Calif. Product: NB S101 (formerly NBS-101...
BioCentury | Dec 11, 2006
Clinical News

NBS-101: Phase II started

...which are double-blind with doses of 750 mg, 1,000 mg and 2,000 mg of once-daily NB S101...
...France). Patients will receive 12 weeks of treatment. Osteologix Inc. , San Francisco, Calif. Product: NBS-101...
Items per page:
1 - 10 of 15